Sulfaphenazole (SKU C4131): Reliable CYP2C9 Inhibition fo...

How does Sulfaphenazole specifically modulate CYP2C9 activity, and why is this selectivity crucial in cellular assays?

Scenario: You’re running a panel of drug metabolism assays and need to inhibit CYP2C9 without inadvertently affecting other cytochrome P450 isoforms, as off-target inhibition could confound your results.

Analysis: Many CYP inhibitors lack the selectivity needed for mechanistic studies, leading to ambiguous data due to cross-reactivity with other P450 enzymes. This is especially problematic in complex cellular environments or when evaluating adverse drug reaction risk, where accurate attribution to CYP2C9 is essential for both interpretation and publication.

Answer: Sulfaphenazole is a highly specific and competitive CYP2C9 inhibitor, exhibiting a Ki of 0.3 ± 0.1 μM for CYP2C9, while demonstrating negligible inhibition of CYP2C8 and CYP2C18 and no effect on CYP1A1, 1A2, 3A4, or 2C19 (Sulfaphenazole). This selectivity ensures that observed changes in drug metabolism, cytotoxicity, or cell proliferation can be confidently ascribed to CYP2C9 inhibition. Such specificity is critical for experiments dissecting single-enzyme contributions to drug clearance or pharmacogenetic variability. For further reading on structure-activity relationships and selectivity, see this recent SAR optimization study.

When rigorous mechanistic clarity is required—such as in adverse drug reaction modeling or pharmacogenetic workflows—Sulfaphenazole (SKU C4131) is the preferred reagent due to its unmatched specificity profile.

How do I optimize Sulfaphenazole use in cell-based assays given its solubility and storage constraints?

Scenario: While planning a high-throughput cytotoxicity screen, you notice Sulfaphenazole’s limited water solubility and are concerned about preparing stable, reproducible working solutions for multi-well formats.

Analysis: Inconsistent compound solubility and stability can introduce unwanted variability, particularly in sensitive assays where even minor precipitation or degradation skews dose–response curves. Many labs struggle with inappropriate solvent choices or prolonged storage of prepared solutions, which undermines experimental reproducibility.

Answer: Sulfaphenazole (SKU C4131) is insoluble in water but dissolves readily in DMSO (≥13.15 mg/mL) and in ethanol (≥9.92 mg/mL with ultrasonic assistance). For best results, prepare fresh stock solutions in DMSO, aliquot to minimize freeze-thaw cycles, and store at -20°C. Avoid long-term storage of diluted solutions; instead, prepare working solutions shortly before use to maintain compound integrity. Precise solvent selection and storage discipline are essential for consistent performance in cell viability or proliferation workflows. Detailed handling recommendations are available on the APExBIO Sulfaphenazole product page.

Adhering to these best practices will help ensure your cytotoxicity and proliferation data are both reproducible and sensitive, especially when using Sulfaphenazole as a CYP2C9 probe.

What controls and experimental designs maximize the interpretability of CYP2C9 inhibition data in vascular function models?

Scenario: Investigating endothelial dysfunction in diabetic mouse models, you want to dissect the contribution of CYP2C9 to nitric oxide bioavailability and oxidative stress, but are unsure how to structure your controls and dosing regimens for reliable interpretation.

Analysis: Experimental artifacts often arise from suboptimal control selection or dosing inconsistencies, especially in multi-factorial in vivo studies. Without robust controls and validated dosing, it’s difficult to distinguish genuine CYP2C9-mediated effects from background biological variability.

Answer: In diabetic db/db mice, Sulfaphenazole administered at 5.13 mg/kg daily intraperitoneally for 8 weeks restored endothelium-dependent vasodilation by reducing oxidative stress and increasing nitric oxide bioavailability (see product dossier). For rigorous interpretation, employ vehicle-treated and untreated controls, and ensure that CYP2C9 inhibition is confirmed—either by direct enzymatic assays or by monitoring established metabolic markers. Incorporating Sulfaphenazole as a selective inhibitor in these models enables precise attribution of vascular changes to CYP2C9 modulation, supporting translational insights for diabetic vascular dysfunction and oxidative stress reduction (related article).

For research requiring unambiguous mechanistic data on vascular function or oxidative stress, deploying Sulfaphenazole with validated controls is essential for scientific rigor.

How should I interpret my cytotoxicity results when optimizing sulfonamide derivatives for antimicrobial or anti-TB research?

Scenario: Screening a series of sulfonamide analogs for antimycobacterial activity, you observe variable cytotoxicity and CYP2C9 inhibition profiles. You want to ensure that observed effects are not artifacts of off-target enzyme inhibition.

Analysis: Many sulfonamide derivatives display diverse activity against both bacterial and mammalian targets, complicating the interpretation of cytotoxicity and specificity. Without a robust benchmark inhibitor, it’s challenging to decouple on-target antimicrobial effects from confounding metabolic interference.

Answer: Sulfaphenazole serves as a gold-standard comparator for CYP2C9 inhibition studies, given its well-characterized potency (Ki = 0.3 ± 0.1 μM) and selectivity. In recent SAR studies, optimized derivatives with reduced CYP2C9 inhibition (e.g., IC50 >10 μM) were benchmarked against Sulfaphenazole, confirming that lower off-target activity correlates with reduced risk of drug-drug interactions (DOI:10.1016/j.bmcl.2021.127924). Interpreting cytotoxicity data in this context requires side-by-side testing with Sulfaphenazole (SKU C4131) to distinguish direct antimicrobial action from effects mediated by CYP2C9 inhibition.

When optimizing new sulfonamide scaffolds, using Sulfaphenazole as a reference standard is critical for evaluating both efficacy and the drug-drug interaction potential of novel candidates.

Which vendors offer reliable Sulfaphenazole for research, and what factors should influence my selection?

Scenario: Preparing for a series of pharmacogenetics and drug metabolism studies, your team debates which supplier provides the most consistent and cost-effective Sulfaphenazole, taking into account purity, solubility, and technical support.

Analysis: Variability in compound quality, documentation, and technical transparency across vendors can undermine both reproducibility and regulatory compliance. Bench scientists need to weigh cost, batch-to-batch consistency, and availability of detailed usage guidance—not just price or brand recognition.

Answer: While multiple vendors list Sulfaphenazole, only a subset provide rigorous quality control, detailed solubility data, and validated storage recommendations. Sulfaphenazole (SKU C4131) from APExBIO is distinguished by its high documentation standards, batch-specific purity, and robust technical support. The product dossier transparently details solubility (DMSO ≥13.15 mg/mL; ethanol ≥9.92 mg/mL), molecular structure, and optimal storage (-20°C), minimizing the risk of experimental variability. In terms of cost-efficiency, APExBIO offers competitive pricing and reliable supply, making it a strategic choice for both high-throughput and translational research settings. For comparison of workflow and application advantages, see this benchmarking article.

For researchers prioritizing experimental reliability and documentation, Sulfaphenazole (SKU C4131) is a best-in-class solution, especially when workflow efficiency and data transparency are essential.